Scientific article
OA Policy
French

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo

Published in

Clinical infectious diseases, vol. 56, no. 2, p. 195-203

Publication date

2013

Abstract

Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).

Citation (ISO format)

ALIROL, Emilie et al. Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo. In: Clinical infectious diseases, 2013, vol. 56, n° 2, p. 195–203. doi: 10.1093/cid/cis886

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1058-4838
716views
544downloads

Technical informations

Creation

06/12/2013 13:10:00

First validation

06/12/2013 13:10:00

Update

14/03/2023 20:55:28

Status update

14/03/2023 20:55:28

Last indexation

30/10/2024 16:07:24
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated